Aug 14, 2023 5:33pm EDT ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Jul 17, 2023 7:00am EDT ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
Jun 30, 2023 8:00am EDT ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
Jun 29, 2023 8:00am EDT CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
May 15, 2023 5:00pm EDT ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 08, 2023 9:00am EDT ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
Apr 25, 2023 5:00pm EDT Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
Apr 24, 2023 7:30am EDT ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting